Mumbai: In a powerful move to address the growing burden of hypertension-induced kidney damage in India, JB Pharma has been recognized by the Asia Book of Records for conducting an unprecedented 17,202 microalbuminuria tests in just one week.
This milestone was achieved as part of the company’s ongoing initiative, “One Mission, Nephro Protection,” aimed at early detection of kidney complications in hypertensive patients.
With World Hypertension Day approaching on May 17, JB Pharma’s record-setting initiative underscores the urgent need for early diagnosis and preventive care in managing hypertension and its impact on kidney health.
“This recognition is a testament to JB Pharma’s unwavering commitment to improving outcomes for hypertensive patients in India,” said Dilip Singh Rathore, President – India Business, JB Pharma.
“We’ve conducted more than 500,000 kidney screenings over the last eight years. This latest achievement reflects our intensified focus on early intervention and proactive nephro protection.”
According to JB Pharma’s data, 18% of the individuals screened during the campaign were hypertensive, and 67.04% of them exhibited early signs of kidney damage—a stark reminder of the hidden risks associated with uncontrolled blood pressure.
“Microalbuminuria testing allows for the early detection of kidney stress in hypertensive individuals, often before chronic kidney disease sets in,” added Vikas Khare, Executive Vice President – Chronic Cluster, India Business, JB Pharma.
“Our record-setting campaign aligns with our belief in responsible, data-driven healthcare and reinforces our commitment to being Good People for Good Health.”
JB Pharma: Driving Impact Through BP Right Karo Campaign
Beyond diagnostics, JB Pharma is actively working to improve hypertension management through its long-standing “BP Right Karo” campaign.
The initiative promotes accurate blood pressure monitoring by aiming to calibrate BP devices across 10,000 clinics in India over the next two to three years. This initiative is crucial, as hypertension and diabetes together account for 40–60% of kidney damage cases in the country.
Through comprehensive screening campaigns and public health education, the company continues to lead in cardiovascular and renal care, enhancing patient outcomes and reinforcing its reputation as a responsible healthcare innovator.
